PE20091336A1 - Derivados de 19-nor-esteroide que tiene un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado y composiciones que los comprenden - Google Patents

Derivados de 19-nor-esteroide que tiene un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado y composiciones que los comprenden

Info

Publication number
PE20091336A1
PE20091336A1 PE2008002179A PE2008002179A PE20091336A1 PE 20091336 A1 PE20091336 A1 PE 20091336A1 PE 2008002179 A PE2008002179 A PE 2008002179A PE 2008002179 A PE2008002179 A PE 2008002179A PE 20091336 A1 PE20091336 A1 PE 20091336A1
Authority
PE
Peru
Prior art keywords
15alpha
alkyl
methylen
pregna
ona
Prior art date
Application number
PE2008002179A
Other languages
English (en)
Inventor
Klar Ulrich
Joachim Kuhnke
Rolf Bohlmann
Jan Huebner
Sven Ring
Thomas Frenzel
Frederik Menges
Steffen Borden
Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40548690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091336(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091336A1 publication Critical patent/PE20091336A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN DERIVADO DE GAMMA-LACTONA DEL ACIDO 15,16-METILEN-17-HIDROXI-19-NOR-17-PREGNA-4,20(Z)-DIEN-3-ONA-21-CARBOXILICO DE FORMULA (I), DONDE Z ES OXIGENO, H, =NOR1 O =NNHSO2R1; R1 ES H, ALQUILO C1-C10, ARILO, ARALQUILO C7-C20; R4 ES H O HALOGENO; R6a Y R6b SON H, ALQUILO C1-C10, ALQUENILO C2-C10, ALQUINILO C2-C10 O JUNTOS FORMAN METILENO O 1,2-ETANDIILO; R7 ES H, ALQUILO C1-C10, CICLOALQUILO C3-C6, ALQUENILO C2-C10, ALQUINILO C2-C10; R18 ES H O ALQUILO C1-C3. SON COMPUESTOS PREFERIDOS: GAMMA-LACTONA DEL ACIDO 17BETA-HIDROXI-15ALFA,16ALFA-METILEN-19-NOR-17ALFA-PREGNA-4-EN-3-ONA-21-CARBOXILICO, GAMMA-LACTONA DEL ACIDO 17BETA-HIDROXI-7ALFA-METIL-15ALFA,16ALFA-METILEN-19-NOR-17ALFA-PREGNA-4-EN-3-ONA-21-CARBOXILICO, GAMMA-LACTONA DEL ACIDO 17BETA-HIDROXI-7BETA-METIL-15ALFA-16ALFA-METILEN-19-NOR-17ALFA-PREGNA-4-EN-3-ONA-21-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD EN EL RECEPTOR DE GESTAGENO Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS MEMOPAUSICOS Y MOLESTIAS PREMENSTRUALES, ENTRE OTROS
PE2008002179A 2007-12-29 2008-12-23 Derivados de 19-nor-esteroide que tiene un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado y composiciones que los comprenden PE20091336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063495A DE102007063495A1 (de) 2007-12-29 2007-12-29 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PE20091336A1 true PE20091336A1 (es) 2009-10-04

Family

ID=40548690

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002179A PE20091336A1 (es) 2007-12-29 2008-12-23 Derivados de 19-nor-esteroide que tiene un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado y composiciones que los comprenden

Country Status (26)

Country Link
US (2) US20100311702A1 (es)
EP (1) EP2238149B1 (es)
JP (1) JP5600071B2 (es)
KR (1) KR20100102136A (es)
CN (1) CN101910192B (es)
AR (1) AR069962A1 (es)
AU (1) AU2008342916A1 (es)
BR (1) BRPI0821666A2 (es)
CA (1) CA2710495C (es)
CL (1) CL2008003919A1 (es)
CO (1) CO6290675A2 (es)
DE (1) DE102007063495A1 (es)
DO (1) DOP2010000199A (es)
EA (1) EA201000982A1 (es)
EC (1) ECSP10010315A (es)
ES (1) ES2539121T3 (es)
HK (1) HK1151532A1 (es)
IL (1) IL206019A0 (es)
NZ (1) NZ586453A (es)
PA (1) PA8810701A1 (es)
PE (1) PE20091336A1 (es)
TW (1) TW200940074A (es)
UA (1) UA98834C2 (es)
UY (1) UY31580A1 (es)
WO (1) WO2009083272A2 (es)
ZA (1) ZA201005395B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334375B2 (en) * 2009-04-10 2012-12-18 Evestra, Inc. Methods for the preparation of drospirenone
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES

Also Published As

Publication number Publication date
WO2009083272A2 (de) 2009-07-09
AR069962A1 (es) 2010-03-03
EA201000982A1 (ru) 2011-02-28
EP2238149A2 (de) 2010-10-13
CA2710495C (en) 2015-04-28
AU2008342916A1 (en) 2009-07-09
JP5600071B2 (ja) 2014-10-01
DE102007063495A1 (de) 2009-09-17
DOP2010000199A (es) 2010-10-15
JP2011507928A (ja) 2011-03-10
ES2539121T3 (es) 2015-06-26
TW200940074A (en) 2009-10-01
ECSP10010315A (es) 2010-08-31
NZ586453A (en) 2012-05-25
EP2238149B1 (de) 2015-03-18
US20100311702A1 (en) 2010-12-09
CO6290675A2 (es) 2011-06-20
US20130123219A1 (en) 2013-05-16
CA2710495A1 (en) 2009-07-09
ZA201005395B (en) 2012-01-25
IL206019A0 (en) 2010-11-30
CN101910192B (zh) 2013-07-31
UY31580A1 (es) 2009-08-03
UA98834C2 (ru) 2012-06-25
CL2008003919A1 (es) 2010-05-07
US8987239B2 (en) 2015-03-24
HK1151532A1 (es) 2012-02-03
BRPI0821666A2 (pt) 2015-06-16
WO2009083272A3 (de) 2009-08-27
CN101910192A (zh) 2010-12-08
KR20100102136A (ko) 2010-09-20
PA8810701A1 (es) 2009-12-16

Similar Documents

Publication Publication Date Title
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
PE20181197A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
ECSP078053A (es) Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
UY29301A1 (es) Derivados amida
UY29614A1 (es) Compuestos químicos
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
PE20110196A1 (es) 5-alquinil-pirimidinas
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal